Founded in May 2022 and headquartered in Chiyoda, Tokyo, FerroptoCure is a drug-discovery startup focused on controlling ferroptosis to create novel cancer treatments. Its lead candidate, FC-004, is advancing toward overseas clinical trials, while additional pipelines are progressing through non-clinical studies. The company plans to use its newly raised funds to finance these trials, strengthen its team for the next development phase, and lay the groundwork for global expansion. FerroptoCure’s approach builds on academic research from Keio University and related national R&D programs. Although the company has not disclosed revenue or patient metrics, it has secured meaningful institutional backing to support its R&D roadmap. The management team, led by CEO Yuji Otsuki, counts investors with deep life-science expertise among its supporters, positioning the company to accelerate development of ferroptosis-based therapies beyond oncology into cardiovascular and neurodegenerative indications. Including its recent Series A and accompanying government grant, FerroptoCure has raised approximately ¥960 million (about $6.5 million) to date.

Total raised

$7M

Funding rounds

2

Latest round

Series A

Latest activity

Sep 2025